Strategies of biotechnology firms towards new, platform technologies

International Journal of Biotechnology

Volumn 3, Issue 1-2, 2001, Pages 23-32

  Persidis, A ^a  

^a RheoGene Inc   (United States)

Author keywords

Biotechnology; Combinatorial drug discovery; Consortia; Gene therapy; Patents; Platform technologies; Polymerase chain reaction; Strategic alliances

Indexed keywords

DRUG THERAPY; GENES; INDUSTRIAL MANAGEMENT; PATENTS AND INVENTIONS; STRATEGIC PLANNING; TECHNOLOGY TRANSFER;

COMBINATORIAL DRUG DISCOVERY; GENE THERAPY; PLATFORM TECHNOLOGIES; POLYMERASE CHAIN REACTION (PCR);

BIOTECHNOLOGY;

EID: 0034973238     PISSN: 09636048     EISSN: None     Source Type: Journal    
DOI: 10.1504/IJBT.2001.000150     Document Type: Article

References (25)

1. Technological discontinuities and organizational environments
2. PCR in the marketplace
3. Enabling technologies and the business of science
4. Critical issues in gene therapy commercialization
5. Drug firms need biotech drug discovery
6. The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry
7. Biotech industry forges new strategies, increases revenues
8. Patterns of strategic choice in emerging firms: Positioning for innovation in biotechnology
9. Combinatorial drug discovery: Which methods will produce the greatest value?
10. Exploring molecular diversity with combinatorial shape libraries
11. Shape space: Is biopharmaceutical discovery entering a new evolutionary stage?
12. Industry trends: Combinatorial chemistry
13. Acquisition as a best-case scenario
14. Drug companies like combinatorial chemistry
15. Biotechnology consortia versus multifirm alliances: Paradigm shift at work?
16. Building molecular value
17. In the rush toward gene therapy, some see a high risk of failure
18. Gene therapy off to slow start
19. An early history of gene transfer and therapy
20. Gene therapy for neurological disorders
21. Genes to the rescue
22. Commercial prospects for gene therapy - A company survey
23. Rhone-Poulenc gambles on treatments; Drug unit sees potential in gene and cell therapy
24. Gene therapy's new business plan
25. Market, investor attitudes challenge developers of biopharmaceuticals